Merck's Oncology Business Will Help It Crush the Bear Market

Cancer is one of the leading causes of death worldwide. That's why it's not surprising that the field of oncology is one of the largest -- and one of the fastest-growing -- in the pharmaceutical industry. 

And while there are plenty of oncology-focused drugmakers out there, Merck (NYSE: MRK) is arguably one of the most prominent of the bunch. The pharma giant has also performed well in the stock market this year, and it could continue on its upward trajectory for many years.

Let's consider why Merck is an excellent cancer-related stock to buy now.

Continue reading

Source Fool.com